Previous studies showed that SOCS1 mutation was a significant predictor of good survival in DLBCL [20, 21] and we also observed a trend of better survival with SOCS1 mutations (PFS: HR 0.55 [95% CI: 0.28–1.08], p = 0.08; Table 2) with a mutational frequency of 21.6% in our cohort. The gene discussed is SOCS1; the disease is diffuse large B-cell lymphoma.